M1 muscarinic agonists: Their potential in treatment and as disease-modifying agents in Alzheimer's disease

Drug Development Research

Volumn 50, Issue 3-4, 2000, Pages 291-297

  Fisher, Abraham ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

AF102B; AF150(S); AF267B; Alzheimer's disease; Amyloid precursor protein; Animal models; Apolipoprotein E; Cholinergic hypofunction; Cognition; G proteins; M1 muscarinic receptors and agonists; Microcebes; Neurotoxicity; Oxidative stress; Sjogren syndrome; Tau; Vicious cycles; amyloid

Indexed keywords

1 METHYLPIPERIDINE 4 SPIRO (2' METHYLTHIAZOLINE); AF 267B; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CEVIMELINE; LEVOFLOXACIN; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE DISEASE; CHOLINERGIC STIMULATION; COGNITION; COGNITIVE DEFECT; DRUG INDICATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; SJOEGREN SYNDROME; XEROSTOMIA;

EID: 0033819271     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2299(200007/08)50:3/4<291::AID-DDR12>3.0.CO;2-6     Document Type: Review

References (67)

1. Novel muscarinic M1 receptor agonists promote survival of CNS neurons in primary cell culture
2. Potential role of muscarinic agonists in Alzheimer's disease
3. Cholinergic deafferentation of the rabbit cortex: A new animal model of A-beta deposition
4. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
5. Microcebus murinus, a convenient laboratory animal for the study of Alzheimer's disease
6. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor
7. Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
8. The effects of the acetylcholinesterase inhibitor ENA713 and the M1 agonist AF150(S) on apolipoprotein E deficient mice
9. Dementia: The neurochemical basis of putative transmitter orientated therapy
10. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from CHO M1 cells
11. New perspectives on developing muscarinic agonists for treating Alzheimer's disease
12. WAL 2014 FU (Talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease
13. Regulated secretion of β-amyloid precursor protein in rat brain
14. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease
15. Muscarinic agonists for the treatment of Alzheimer's disease: Progress and perspectives
16. Muscarinic receptor agonists in Alzheimer's disease. More than just symptomatic treatment
17. Progress and perspectives in new muscarinic agonists
18. M1 muscarinic agonist treatment reverses cognitive and cholinergic impairments of apolipoprotein E-deficient mice
19. Novel M1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: A unifying hypothesis
20. The influence of cholinergic mechanisms on neurodegeneration due to beta-amyloids and tau phosphorylation (translated from Portuguese)
21. Muscarinic agonists reduce tau phosphorylation in transfected cells and in neurons
22. Sjogren syndrome: New approaches to treatment
23. Site-specific dephosphorylation of tau in apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment
24. Quantitative analysis of tau protein-immunoreactive accumulations and beta-amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus
25. Muscarinic agonists in Alzheimer's disease
26. Discrete activation of transduction pathways associated with acetylcholine M1 receptor by several muscarinic ligands
27. NGF-dependent neurotrophic-like effects of AF102B, an M1 muscarinic agonist, in PC12M1 cells
28. Amyloid precursor protein secretion via muscarinic receptors: Reduced desensitization using the M1-selective agonist AF102B
29. Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the M1 muscarinic receptor to amyloid precursor protein secretion
30. Modulation of beta-amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors
31. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease
32. Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis: Possible role in cholinergic dysfunction in Alzheimer's disease
33. Activation of protein kinase C inhibits cellular production of the amyloid β-protein
34. Tau protein in normal and Alzheimer's disease brain: An update
35. Cholinergic muscarinic receptor signaling by phosphoinositides signal transduction system in Alzheimer's disease
36. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices
37. Amyloid β-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons
38. Pharmacological drug treatment of Alzheimer disease: The cholinergic system revisited
39. Regional alteations in M1 muscarinic receptor-G protein coupling in Alzheimer's disease
40. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation
41. SB202026: A novel muscarinic partial agonist with functional selectivity for M2 receptors
42. The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes
43. Pharmacological in vitro characterization of the arecoline bioisostere, Lu 25-109-T, a muscarinic compound with M1-agonistic and M2/M3-antagonistic properties
44. Muscarinic stimulation promotes cultured Purkinje cell survival: A role for acetylcholine in cerebellar development?
45. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain
46. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
47. Alzheimer's disease: Relationship between muscarinic cholinergic receptors, beta-amyloid and tau proteins
48. Clinical neurochemistry: Developments in dementia research based on brain bank material
49. Growth-factor like effects mediated by muscarinic receptors in PC12M1 cells
50. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum
51. Lesion of septal-hippocampal neurons with 192 IgG-saporin alters function of M1 muscarinic receptors
52. In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity
53. Activation of M1-muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells
54. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester
55. Muscarinic receptor agonists under development for the treatment of Alzheimer's disease
56. Milameline (CI-979/RU35926): A muscarinic receptor agonist with cognition-activating properties: Bichemical and in vivo characterization
57. Beta-amyloid protein precursor in Microcebus murinus: Genotyping and brain localization
58. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists
59. Pharmacological studies on novel muscarinic agonists, 1-oxa-8-azaspiro[4.5]decane derivatives YM796 and YM954
60. A protein factor essential for microtubule assembly
61. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells
62. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry